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Patients who survive sepsis can develop long-term immune dysfunction, with expansion of
the regulatory T (Treg) cell population. However, how Treg cells proliferate in these patients is
not clear. Here we show that IL-33 has a major function in the induction of this immuno-
suppression. Mice deﬁcient in ST2 (IL-33R) develop attenuated immunosuppression in cases
that survive sepsis, whereas treatment of naive wild-type mice with IL-33 induces immu-
nosuppression. IL-33, released during tissue injury in sepsis, activates type 2 innate lymphoid
cells, which promote polarization of M2 macrophages, thereby enhancing expansion of the
Treg cell population via IL-10. Moreover, sepsis-surviving patients have more Treg cells, IL-33
and IL-10 in their peripheral blood. Our study suggests that targeting IL-33 may be an
effective treatment for sepsis-induced immunosuppression.
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S
epsis is an systemic inﬂammatory response triggered by
acute infection that leads to progressive multi-organ
dysfunction1. Advances in supportive care have resulted
in an increase in the survival rate of sepsis patients2; however,
these patients have a poor long-term outcome, with risk of
cognitive and physical impairments3–5.
Compelling experimental and clinical evidence indicates that
sepsis can cause immunosuppression that accounts for secondary,
mostly opportunistic, infections6–9. Consistent with this evidence
is that patients with septic shock have an increased frequency of
circulating regulatory T (Treg) cells that correlates with
immunosuppression10,11. Experimentally, we and others have
reported an increase in the number of Treg cells in the spleen of
mice which survived sepsis (hence forward called sepsis-
survivors), and involvement of these cells in long-term sepsis-
induced immune dysfunction12,13. However, the mechanisms of
the induction of Tregs in the long-term immunosuppression in
sepsis survivors are obscure.
IL-33, an IL-1 cytokine family member, is an important
mediator of type 2 immune responses14. Binding to a heterodimer
receptor that consists of ST2 (IL-33R, IL1RL1) and IL-1 receptor
accessory protein (IL-1RAcP), mature IL-33 induces the
production of IL-4, IL-5, IL-10 and IL-13 from eosinophils,
mast cells, T-helper 2 (Th2) cells and type 2 innate lymphoid cells
(ILC2s)15,16. Moreover, IL-33 can synergize with IL-4 to promote
M2 macrophage polarization17. Studies have also highlighted the
critical role of IL-33 as an immunomodulatory cytokine that
induces the expansion of Treg cell populations18–22.
Here, we show that endogenous IL-33, released in response to
severe tissue damage, has an essential function in the expansion
of Treg cells after sepsis and in the development of long-term
sepsis-induced immunosuppression. IL-33 activates ILC2s, which
produce IL-4 and IL-13 that drive M2 polarization of macro-
phages, resulting in the expansion of Treg cell population via the
production of IL-10. Furthermore, neutralization of IL-33 with
soluble ST2 (sST2, a decoy receptor for IL-33) limits the
immunosuppressive effect of sepsis and reduces mortality of
mice affected by secondary infection. Importantly, patients who
survive sepsis have more circulating Treg cells and higher
concentrations of IL-33 and IL-10 in their serum compared to
healthy non-sepsis individuals. Our data, therefore, uncover a
function of IL-33 in sepsis-induced immunosuppression and
identify a target for potential treatment of this adverse long-term
outcome induced by sepsis.
Results
IL-33 is critical for sepsis-induced immunosuppression. Severe
sepsis was performed in mice using a clinically relevant model of
polymicrobial peritonitis induced by caecal ligation and puncture
(CLP), which has been used extensively to investigate sep-
sis12,13,23–27. BALB/c mice undergoing lethal CLP were treated
with antibiotics (Supplementary Fig. 1a,b). In this lethal CLP
model, as oppose to the sub-lethal models, all the wild type (WT)
and ST2-deﬁcient mice (Il1rl1 / ) would not survive the
procedure unless rescued (40%) by the treatment of antibiotics.
CLP led to an early and simultaneous pro- and anti-inﬂammatory
response, as evidenced by increased levels of IL-1b, IL-6, TNF and
IL-10 in serum and lungs of mice that resolved by 72 h
(Supplementary Fig. 1c,d). Moreover, a rapid development of
multiple organ failures was observed after CLP, as assessed by
increased serum concentrations of endocan (endothelial cell
dysfunction marker), creatine kinase-MB (heart injury marker),
alanine aminotransferase (liver injury marker) and blood urea
nitrogen (kidney function marker) (Supplementary Fig. 1e).
However, all the injury/dysfunction serum markers assessed
returned to basal levels by 72 h after CLP in sepsis-surviving mice
treated with antibiotics (Supplementary Fig. 1c–e). Sepsis-
surviving mice show a progressive clearance of bacteraemia,
which was undetectable 15 days after CLP (Supplementary
Fig. 1b). Nevertheless, we observed an increasing production of
type 2 cytokines (IL-4 and IL-13) and IL-33 in the lung tissue
homogenates and bronchial lavage (BAL) ﬂuids of sepsis-
surviving mice at later time points, starting at day 3 after CLP
and remaining elevated over the course of observation (Fig. 1a;
Supplementary Fig. 2).
The increased production of IL-33 in sepsis-surviving mice at a
later stage of CLP prompted us to investigate whether this
cytokine plays a role in the development of long-term sepsis-
induced immunosuppression. As previously described12, the
challenge of sepsis-surviving WT mice with an intranasal sub-
lethal dose of Legionella pneumophila at day 15 after CLP resulted
in 100% mortality, whereas all naive mice survived (Fig. 1b). The
high-susceptibility of sepsis-surviving mice to L. pneumophila
infection was not accompanied by changes in the production of
pro-inﬂammatory cytokines, such as TNF and IL-6
(Supplementary Fig. 3). Intriguingly, Il1rl1 / mice that
survived from sepsis were more resistant to a subsequent
challenge infection with L. pneumophila (Fig. 1b). Consistent
with these results, sepsis-surviving Il1rl1 / mice show a
signiﬁcantly lower L. pneumophila growth in the lung and
spleen than in those of the WT mice (Fig. 1c). Although sepsis-
surviving Il1rl1 / mice had higher production of IL-33 than
WT mice, they failed to produce more IL-4 and IL-13 in the lungs
compared to the naive control mice at day 15 after CLP (Fig. 1d).
The increased level of IL-33 detected may reﬂect the
accumulation of IL-33 in the absence of ST2, while IL-4/IL-13
is downstream of IL-33/ST2 signalling. In a reverse experiment,
intranasal administration of recombinant IL-33 to naive WT mice
daily over a 4-days period resulted in increased susceptibility to
the following challenge with L. pneumophila infection (Fig. 1e),
and impaired bacterial clearance from the lungs in a dose-
dependent manner (Fig. 1f; Supplementary Fig. 4a). Treatment
with IL-33 also resulted in increased production of IL-4 and IL-13
in the lungs of WT mice (Fig. 1g; Supplementary Fig. 4b). In
contrast, IL-33 had no effect on similarly treated naive Il1rl1 /
mice (Fig. 1e–g). These results demonstrate the important role
and speciﬁcity of IL-33 in the induction of immunosuppression
associated with an increased type 2 cytokines production.
We then examined the potential therapeutic effect of
neutralizing IL-33 in the surviving sepsis mice using the IL-33
decoy receptor, soluble ST2 (sST2). Treatment of WT mice with
sST2 signiﬁcantly protected sepsis-surviving mice from the
following infection with L. pneumophila (Fig. 1h). There were
no difference in survival between Il1rl1 / and WT mice and
mice treated with sST2 and vehicle with CLP-induced sepsis
receiving antibiotics (Supplementary Fig. 5a,b).
IL-33 induces ILC2 expansion in sepsis-surviving mice. IL-33 is
a key inducer of ILC2 expansion, which is an important cellular
source of type 2 cytokines28–32. We found a marked increase in
lineage-negative (Lin ) (CD3CD11cCD19F4/80 )
ST2þSca1þCD45þ ILC2s in the lung of sepsis-surviving mice
that peaked on day 3 after CLP (Fig. 2a,b). ILC2s
(LinSca1þCD45þ cells) were present in mice of both
C57BL/6 J and BALB/c backgrounds, although consistently
more abundant in C57BL/6 J mice (Supplementary Fig. 6a). A
similar increase of ILC2 was observed in the lung of sepsis-
surviving Rag1 / mice that lack mature T- and B-lymphocytes
(Supplementary Fig. 6b). However, ILC2s were signiﬁcantly
reduced in the lungs of sepsis-surviving Il1rl1 /mice compared
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to WT mice (Fig. 2c). Correspondingly, we found a signiﬁcantly
lower number of IL-13-producing ILC2s in the lung of sepsis-
surviving Il1rl1 / mice on day 7 after CLP compared to sepsis-
surviving WT mice (Fig. 2d). Moreover, sepsis-surviving Rag1 /
mice showed similar levels of IL-4 and IL-13 in the lungs as
those found in sepsis-surviving WT mice (Fig. 2e). Altogether
these results indicate that IL-33 plays a crucial role in the
expansion of ILC2s after CLP-induced sepsis, which are
mediating the early production of type 2 cytokines in sepsis-
surviving mice.
Type 2 cytokines mediate sepsis-induced immunosuppression.
The prominent features of ILC2s and type 2 cytokines in sepsis-
induced susceptibility to secondary infection prompted us to
examine the role of these cytokines in the development of sepsis-
induced immunosuppression. To this end, we performed
experiments on Stat6 / mice, since signalling for both IL-4 and
IL-13 is markedly impaired in the absence of STAT6 (ref. 33).
There was no difference in survival between Stat6 / and WT
mice with CLP-induced sepsis receiving antibiotics
(Supplementary Fig. 5c). However, sepsis-surviving Stat6 /
mice were more resistant to subsequent infection with L. pneu-
mophila (Fig. 3a). Moreover, sepsis-surviving Stat6 / mice
showed signiﬁcantly lower bacterial burdens in the lungs and
spleen than those of the WT mice after L. pneumophila challenge
(Fig. 3b). Similar to ﬁndings obtained with sepsis-surviving
Il1rl1 / mice, the production of IL-4 and IL-13 was markedly
reduced in the lungs of Stat6 / mice on day 15 after CLP
(Fig. 3c), indicating that these type 2 cytokines can induce their
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Figure 1 | IL-33 is critical for sepsis-induced immunosuppression. (a) IL-33 concentrations in the lungs of BALB/c mice undergoing CLP and antibiotic
treatment were determined by ELISA (nZ4 mice per group). (b–d) Surviving BALB/c and Il1rl1 / mice undergoing CLP and antibiotics were challenged
with L. pneumophila 15 days after CLP. (b) Survival curves after challenge (n¼ 30 mice for naive group, n¼ 35 mice for WT CLP group and n¼ 31 mice for
Il1rl1 / CLP group). (c) Bacterial loads in lungs and spleen 24 h after challenge (n¼ 10 mice per group). (d) Concentrations of IL-4, IL-13 and IL-33 in the
lungs 15 days after CLP determined by ELISA (nZ4 mice per group). (e–g) BALB/c and Il1rl1 / mice were inoculated i.n. with IL-33 or PBS for 4
consecutive days and challenged i.n. 2 days later with L. pneumophila. (e) Survival curves (n¼ 10 mice per group). (f) Bacterial load in the lung tissue 48 h
after challenge (n¼ 5 mice per group). (g) IL-4 and IL-13 concentrations in the lung tissue 48 h after challenge (n¼ 5 mice per group). (h) BALB/c mice
undergoing CLP and antibiotics were injected i.p. with sST2 or PBS. The sepsis-surviving mice were challenged with L. pneumophila on day 15 (n¼ 10 mice
per group). *Po0.05 and **Po0.01 (one-way ANOVA result with Dunnett posthoc tests in a, Mantel–Cox log-rank test in b,e,h, Mann–Whitney U test in
c,f and two-tailed unpaired Student’s t-test in d,g). Data are one experiment (h); or representative of two (a,b,g) or three (d,f) independent experiments
with similar results; or pooled from two (e) or six (b) independent experiments (mean±s.e.m. in a,d,g and median in c,f).
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synthesis in a positive feedback loop in an STAT6-dependent
manner. However, STAT6-deﬁciency did not reduce the amount
of IL-33 in the lungs of sepsis-surviving mice (Fig. 3c), again
indicating that the function of IL-33 is upstream of type 2 cyto-
kines in the present system. Indeed, repeated intranasal admin-
istration of IL-33-induced lower levels of IL-4 and IL-13
production in the lungs of Stat6 / mice compared to that of
the WT mice (Fig. 3d). Moreover, exogenous IL-33 treatment did
not affect the resistance of Stat6 / mice to subsequent chal-
lenge infection with L. pneumophila (Fig. 3e,f). Collectively, these
results indicate that type 2 cytokines mediate the development of
sepsis-induced immunosuppression, an effect regulated by IL-33/
ST2 signalling.
Polarization of M2-like macrophages in sepsis-surviving mice.
IL-4 and IL-13 are prototypical cytokines that drive the polar-
ization of macrophage toward an M2 phenotype34. We next
investigated the kinetics of macrophage polarization in mice after
sepsis induction. We found up-regulation of Cebpb mRNA, a
transcription factor required for expression of M2-associated
genes35, in the lung tissue of mice by day 3 and 7 after CLP
(Fig. 4a). Moreover, we also detected high-expression of the
canonical M2-associated transcripts, Arg1 (encoding arginase-1)
and Mrc1 (encoding mannose receptor, CD206), as well as an up-
regulation of the wound healing-related gene Igf1 (encoding IGF-
1), in the lung tissues of sepsis-surviving mice by day 10 and 15
after CLP (Fig. 4a). Concordantly, increased expression of Arg1,
Mrc1 and Retnla (encoding Fizz-1) was found in a CD11bþ
macrophage-enriched population isolated from the lungs of
sepsis-surviving mice by day 10 after CLP (Fig. 4b). Consistent
with these results, high concentrations of IGF-1 and M2-derived
chemokines CCL17 and CCL22 protein were found in the lung
tissue homogenates by day 10 and 15 after CLP (Fig. 4c).
Furthermore, we also found increased expression of CD206 in F4/
80lowperitoneal macrophages from sepsis-surviving mice by day 3
after CLP; reaching peak levels at day 10 and maintained at an
elevated level by day 15 (Fig. 4d). Consistent with this
observation, increased expression of Arg1 protein was also
observed in peritoneal macrophages harvested from sepsis-
surviving mice 15 days after CLP when compared to that of the
naive mice (Fig. 4e). Low-expression of F4/80 is characteristic of
macrophages recruited to the serous cavities under inﬂammatory
conditions36,37.
As demonstrated previously17, we conﬁrmed that IL-33
strongly enhances the polarization of IL-4 treated bone
marrow-derived macrophages (BMDMs) toward M2 phenotype,
as assessed by the CD206 expression (by ﬂow cytometry) and
production of CCL22 (by ELISA), an effect that was abrogated in
Il1rl1 / BMDMs (Supplementary Fig. 7). Moreover, the
expression of M2 markers was also completely absent in IL-4
treated Stat6 / BMDMs (Supplementary Fig. 7). We then
addressed the contribution of type 2 cytokines and IL-33 on M2
polarization of macrophages in sepsis-surviving mice. Consistent
with the increased production of IL-4 and IL-13 found in the
sepsis-surviving Rag1 / mice (Fig. 2e), adaptive immunity was
not required for the polarization of peritoneal macrophages
toward M2 phenotype, since sepsis-surviving Rag1 / mice
showed a similar frequency of peritoneal macrophage expressing
CD206 as the WT mice (Fig. 5a). Instead, we found that ST2 and
STAT6 signalling were required for M2 polarization since the
expression of CD206 was not increased in peritoneal
macrophages from sepsis-surviving Il1rl1 / or Stat6 /
mice (Fig. 5b). Accordingly, arginase activity assessed indirectly
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by urea production was considerably lower in the peritoneal
lavage and BAL ﬂuids from sepsis-surviving Il1rl1 / and
Stat6 / mice than in those from the WT controls
(Supplementary Fig. 8a,b). Moreover, production of IGF-1
protein in the lung was also reduced in the lungs of sepsis-
surviving Il1rl1 / or Stat6 / mice (Supplementary Fig. 8c).
Previous studies demonstrated that IL-33 signalling ampliﬁes
M2 macrophage polarization through up-regulation of IL-4
receptor-a (IL-4Ra) expression, resulting in an increased IL-4
response17. We then analysed peritoneal macrophages from
sepsis-surviving mice by ﬂow cytometry and observed increased
expression of IL-4Ra compared to that of the naive mice (Fig. 5c).
Accordingly, IL-4 stimulation induced higher STAT6
phosphorylation in peritoneal macrophages from sepsis-
surviving WT mice than that observed in the macrophages
from naive mice, an effect that was abrogated in macrophages
from sepsis-surviving Il1rl1 / mice (Fig. 5d). Consistent with
these ﬁndings, peritoneal macrophages from sepsis-surviving WT
mice released a larger amount of CCL22 in the presence of IL-4,
while macrophages from Il1rl1 / and Stat6 / mice
produced a low-level of this M2-deﬁved chemokine (Fig. 5e).
While M2 macrophages are involved in tissue repair and
immune-regulation, bactericidal activity is considered a cardinal
feature of M1 macrophages38. We next investigated the
bactericidal activity of M2-like macrophages from surviving
sepsis mice. To this end, peritoneal macrophages isolated from
sepsis-surviving mice at day 15 after CLP were incubated with
L. pneumophila and intracellular bactericidal activity was assessed
by quantiﬁcation of the intracellular viable bacterial load.
Macrophages from sepsis-surviving mice showed substantially
more intracellular bacterial load than macrophages from the
control naive mice indicating impaired bactericidal ability of the
macrophages from sepsis-surviving mice. Importantly,
macrophages recovered from sepsis-surviving Il1rl1 / and
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Stat6 / mice harboured signiﬁcantly fewer bacteria than
macrophages from sepsis-surviving WT mice (Fig. 5f), showing
the key role of ST2 and STAT6 in the impaired bactericidal
activity of the macrophage from sepsis-surviving mice.
Interestingly, pharmacological inhibition of arginase with S-(2-
boronoethyl)-l-cysteine (BEC) markedly enhanced the
bactericidal activity of macrophages from sepsis-surviving mice,
indicating that arginase activity contributes, at least in part, to the
impaired bactericidal ability of these cells (Fig. 5f). Consistent
with these ﬁndings, BMDMs polarized to M2 phenotype also
exhibited reduced ability to control intracellular L. pneumophila
growth compared with non-polarized M0 macrophages. The
bactericidal activity of the polarized M2 macrophages was also
improved by arginase inhibition (Fig. 5g).
We then determined the role of M2 macrophages in the
susceptibility of mice to L. pneumophila infection in vivo.
Adoptive transfer of M2-polarized BMDMs, but not M0, into
naive mice increased the susceptibility of the recipients to a
challenge with L. pneumophila infection (Fig. 5h), similar to those
observed with exogenous IL-33 treatment (Fig. 1e). Taken
together, these data demonstrate a robust macrophage repro-
gramming toward an M2 phenotype in sepsis-surviving mice
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induced by type 2 cytokines and IL-33, presumably associated
with the development of a wound healing response. However, the
switch of macrophages toward M2 polarization may contribute
to the development of long-term sepsis-induced immuno-
suppression.
M2 promotes Treg differentiation in sepsis-surviving mice.
Since IL-33 can expand Treg cell population and these cells have
been shown to mediate sepsis-induced immunosuppression, we
next investigated the potential function of IL-33 in the induction
of Treg cells in CLP-induced immune dysfunction. At day 15
after CLP, a signiﬁcantly higher frequency and an absolute
number of CD4þFoxp3þ Treg cells expressing ST2 were found
in the spleen of sepsis-surviving mice as compared to naive mice
(Fig. 6a,b). However, the frequency and the absolute number of
Treg cells were not increased in the spleens of sepsis-surviving
Il1rl1 / or Stat6 / mice (Fig. 6b,c). Since ST2 and STAT6
signalling were critical to induce M2 polarization in sepsis-sur-
viving mice, we examined whether M2 macrophages might
induce the generation of Treg cells. BMDMs from naive mice
(M0) were polarized into M2 (with IL-33/IL-4/IL-13) and co-
cultured with naive CD25CD4þ T cells in the presence of
exogenous IL-2 and anti-CD3 but in the absence of TGF-b. As
expected, few naive CD4þ T cells expressed Foxp3 after 4 days
under this culture condition. However, M2 macrophages, but not
M0, substantially increased the percentage of CD4þ T cell
expressing Foxp3 (Fig. 6d). We then examined whether M2
macrophages were responsible for the expansion of Treg cells in
sepsis-surviving mice. M2 macrophages were adoptively
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transferred into Stat6 / mice 3 days after CLP induction and
Treg cell generation was monitored. After 12 days, M2-recipient
Stat6 / mice showed a marked increase in the frequency and
the total number of Treg cells in their spleen compared to those
receiving M0 macrophages or PBS (Fig. 6e; Supplementary
Fig. 9a). These mice also had impaired resistance to a subsequent
challenge infection with L. pneumophila (Fig. 6f; Supplementary
Fig. 9b). Collectively, these data indicate that ST2 signalling and
M2 macrophages are involved in the expansion of Treg cell
population in sepsis-surviving mice.
IL-10 promotes Treg cell expansion in sepsis-surviving mice.
To further address the mechanism underlining the enhancement
of Treg differentiation by M2 macrophages, we investigated the
contribution of IL-10. Neutralization of IL-10 bioactivity with
anti-IL-10 antibody markedly reduced the expression of Foxp3 in
CD4þ T cells induced by co-culture with M2 macrophages
(Fig. 7a). Moreover, Il10 / M2 macrophages induced lower
frequency of CD4þFoxp3þ T cells than WT M2 macrophages
when co-cultured with CD4þCD25 T cells from WT or Il10 /
mice (Fig. 7b). These data suggest that M2 macrophage-derived
IL-10 is involved in the expansion of Treg cells in sepsis-surviving
mice.
We then examined whether IL-10 participates in the
pathogenesis of immune dysfunction in sepsis-surviving mice.
In agreement with data from M2 polarization kinetics, we found
an increased concentration of IL-10 in the lungs of sepsis-
surviving mice by day 3 after CLP, remaining elevated over the
course of observation (Supplementary Fig. 10a). Concordantly,
sepsis-surviving Rag1 / mice, which had increased the
polarization of M2 macrophages (Fig. 5a), also showed elevated
concentration of IL-10 in the lungs (Supplementary Fig. 10b). In
contrast, the production of IL-10 in the lungs of Il1rl1 / and
Stat6 / mice was markedly reduced at day 15 after CLP
(Supplementary Fig. 10c,d), suggesting that type 2 cytokines and
IL-33 are involved in the production of IL-10 in sepsis-surviving
mice. Interestingly, we found that Il10 / and WT mice show a
high and comparable concentration of IL-4 and IL-33 in the lungs
and a similar frequency of peritoneal M2 macrophages (F4/80þ
CD206þ cells) at day 15 after CLP (Supplementary Fig. 11).
Thus, these data suggest that IL-10 is not required for
polarization of macrophage toward M2-like phenotype and
acting downstream of M2 macrophages in sepsis-surviving mice.
The frequency and the absolute number of splenic CD4þ
Foxp3þ Treg cells were marked reduced in Il10 / sepsis-
surviving mice at day 15 after CLP (Fig. 7c). Finally, sepsis-
surviving Il10 / mice show signiﬁcantly lower bacterial
burdens in the lungs and spleen and higher survival rate to
challenge with L. pneumophila infection than the WT control
mice (Fig. 7d,e). There were no differences in survival between
Il10 / and WT mice with CLP-induced sepsis receiving
antibiotics (Supplementary Fig. 5d). Altogether, these data
indicate that IL-10 derived from M2 macrophages is required
for Treg cells expansion and, consequently, for the immune
dysfunction in sepsis-surviving mice.
Sepsis survivors have more Treg cells, IL-33 and IL-10. To
demonstrate the clinical relevance of our ﬁndings, we examined
sepsis-surviving patients. A total of 11 patients admitted to the
intensive care unit, who met the inclusion and exclusion criteria
and survived after treatment of sepsis were prospectively enroled
into the study. Peripheral blood from sepsis survivors was col-
lected 5–10 months after sepsis diagnosis and analysed for the
frequency, and the absolute number of CD4þFoxp3þ T cells and
serum concentration of IL-33 and IL-10 together with age- and
sex-matched healthy volunteer blood donors (n¼ 14). The
demographic and clinical characteristics of the patients are shown
in Supplementary Tables 1 and 2. The total number of leukocytes
was increased in sepsis survivors when compared to healthy
controls, which was mainly due to the increase in the number of
monocytes (Supplementary Fig. 12). Sepsis-surviving patients had
signiﬁcantly higher concentrations of IL-33 and IL-10 in their
serum and more circulating Treg cells compared to those of the
healthy controls (Fig. 8a,b). These data are consistent with the
notion that our ﬁnding in the mouse model (summarized in
Fig. 8c) may be translated to the clinical scenario.
Discussion
Data presented here show that IL-33/ST2 signalling leads to a
signiﬁcant expansion of Foxp3þ Treg cell population expressing
ST2 in sepsis-surviving mice. This mechanism not only accounts
for, at least in part, the development of long-term sepsis-induced
immune dysfunction but also suggests that blocking IL-33 or ST2
are potential targets for treating this immunological sequel in
sepsis survivors.
Epithelial and endothelial cells in most organs express IL-33
constitutively39, which can act as an endogenous danger signal or
alarmin released in response to tissue damage40. Moreover,
myeloid cells can also release IL-33 in response to pro-
inﬂammatory cytokines or TLR ligands41,42. In this study, we
show that IL-33 increases in response to the systemic
inﬂammation and tissue damage caused by experimental septic
peritonitis, remaining elevated in the lung tissue for days after
recovery from sepsis. Moreover, we show that IL-33 induces the
expansion of ILC2 populations and the subsequent production of
IL-4 and IL13, which together with IL-33 induce a pronounced
macrophage reprogramming toward an M2-like phenotype in
sepsis-surviving mice. In the absence of ST2, ILC2 expansion and
type 2 cytokines production is abolished. Also, increased
production of IL-4 and IL-13, as well as M2 polarization, is
maintained in sepsis-surviving Rag1 /mice. These results
suggest that IL-33-induced ILC2s rather than T helper-2 cells
are likely the source of type 2 cytokines observed in sepsis
survivors, but the participation of other cells types such as
macrophages is not excluded. Conversely, sepsis-surviving mice
lacking ST2 or STAT6 do not show polarization of M2-like
macrophage, indicating that type 2 cytokines and IL-33 are
critically involved in the polarization of M2 macrophages in
sepsis-surviving mice. Consistent with this observation, increased
number of circulating M2 macrophage was reported in septic
patients43.
In the CLP-induced sepsis, there is no complete resolution of
the inﬂammation as long as the abscesses surrounding the
devitalized caecum remains in survivors. Indeed, it was previously
reported that IL-13 concentration increases in the lungs and
kidneys of mice during late CLP and that its neutralization
worsens tissue inﬂammation and organ dysfunction44. Consistent
with the effect of IL-13 on M2 polarization, we found that many
factors involved in tissue repair, including Arg1, IGF-1 and TGF-
b1 (ref. 45), are up-regulated in lungs of sepsis-surviving mice. In
line with this observation, both ILC2s and M2 macrophages have
been reported to be involved in the wound healing process and
tissue repair30,45. Collectively, our results illustrate the dynamic
series of molecular and cellular events in CLP-induced sepsis
survivors, in which IL-33 may primarily function as an alarmin
that rapidly responds to injurious signals and provides early
instruction toward the repair process.
Earlier studies have demonstrated an increase in the number of
Treg cells in the spleen of sepsis-surviving mice, which are
involved the development of long-term sepsis-induced immune
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dysfunction12,13. Herein we show that genetic deletion of ST2 and
STAT6 prevents the expansion of Foxp3þ Treg cell population in
sepsis-surviving mice, concomitant with a marked improvement
in the survival rate after secondary pneumonia induced by
L. pneumophila infection. These results implicate IL-33 and IL-4/
IL-13 signalling in the expansion of Treg cell population and the
development of long-term sepsis-induced dysfunction. In a
previous report, we showed that exogenous IL-33 can also
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protect mice against CLP by rapidly mobilizing neutrophils into
the infectious focus to kill the pathogens during acute sepsis46.
Thus, the induction and release of IL-33 during sepsis is a ‘trade-
off’ between the protection from an initial acute condition
(such as resistance to primary infection and induction of tissue
repair) and the subsequent manifestation of long-term
immunosuppression. This ‘trade-off’ could also explain why
blocking IL-33/ST2 signalling could not completely protect the
sepsis-surviving mice from the secondary challenge infection.
M2 macrophages can induce the differentiation of regulatory T
cells47. Moreover, CCR4, the receptor for M2-derived
chemokine’s CCL17 and CCL22, plays a detrimental role in
acute sepsis and contributes to the suppressive function of Tregs
in sepsis-surviving mice48,49. Since ST2 and STAT6 signalling
were required for the differentiation of M2 macrophages in sepsis
survivors, we hypothesized that M2 macrophages might
contribute to the expansion Treg cell population in sepsis-
surviving mice. In vitro, we found that M2-polarized
macrophages can efﬁciently induce Treg cell generation, at least
in part, in an IL-10-dependent manner. Moreover, adoptive
transference of M2-polarized macrophages into sepsis-surviving
mice lacking STAT6 markedly induces expansion of Treg cell
population and increases susceptibility to secondary pneumonia
induced by L. pneumophila. Finally, we demonstrated that
deﬁciency of IL-10 prevents the increase of Treg cell population
in sepsis-surviving mice and improves survival from secondary
pneumonia caused by L. pneumophila. Indeed, IL-10 can
potentiate differentiation of TGFb-induced Foxp3þ Treg cells
via STAT3 activation50. Moreover, it was previously shown that
neutralization of IL-4, IL-10 and TGF-b reduces expansion Treg
cell population and improves cell-mediated immunity in septic
mice11,51. Collectively, these data indicate that IL-33/ST2 and IL-
4/IL-13/STAT6 signalling are required for the expansion of Treg
cells in sepsis-surviving mice, linking IL-10-secreting M2
macrophage in this process. The Treg cells from sepsis-
surviving mice expressed a signiﬁcant level of ST2. It is thus
possible that IL-33 could also directly activate the Treg cell
populations expanded by the M2/IL-10 pathway (Fig. 8c).
Although there are differences among the subsets of macro-
phages such as M2 macrophage, tumour-associated macrophage,
regulatory macrophage and monocytic myeloid-derived suppres-
sor cell (MDSC), they all share several surface markers and also
exhibit immune suppressive activities. In this context, it was
demonstrated that IL-33 could also expand MDSCs, which in
turn generate periphery-induced Foxp3þ Treg cells mediating
cardiac and skin allograft survival18,52. Moreover, it was reported
that an MyD88-dependent MDSC population that express IL-10
expanded after CLP in mice, contributing to the T cell
suppression seen after sepsis53. Therefore, we cannot exclude
the possibility that IL-33-induced MDSCs also participate in the
production of IL-10 and expansion of Treg cells in sepsis
survivors.
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Our ﬁnding in the mouse model is likely to apply to clinical
sepsis. At 5-10 months after sepsis diagnosis, sepsis survivors
have signiﬁcantly more circulating Foxp3þ Treg cells and also
higher concentrations of IL-33 and IL-10 in their serum
compared to those of the healthy controls. However, we have
only been able to enrol into the study patients with severe sepsis
or septic shock. Thus, whether the severity of septic episode
would impact on the degree of the long-term immune
dysfunction in sepsis survivors is currently unclear and merits
further investigation together with the identiﬁcation of the
cellular sources of IL-33 in sepsis.
In summary, our results have identiﬁed a previously unrecog-
nized dual role of IL-33 in sepsis survivors. IL-33, released during
the widespread tissue injury, induces ILC2s expansion and M2
polarization of macrophages in sepsis survivors, promoting a
wound healing process. However, IL-33-induced IL-10-secreting
M2 macrophages increase the expansion of Treg cell population,
thereby contributing to the development of long-term sepsis-
induced immunosuppression. Our study raises the possibility of
targeting IL-33 to ameliorate sepsis-induced long-term immuno-
suppression following recovery from infection.
Methods
Mice. BALB/c and C57BL/6 J mice were purchased from Charles River. Il1rl1 /
(deﬁcient for ST2) mice on C57BL/6 background were originally provided by Dr
Andrew McKenzie (LMB, Cambridge)54. Il1rl1 / mice on BALB/c background
were generated as described55. Stat6 / mice on BALB/c background and Il10 /
and Rag1 / on C57BL/6 J background were purchased from Jackson Laboratories.
All mice were bred and maintained under speciﬁc pathogen-free conditions at the
Animal Facility of the School of Medicine of Ribeira˜o Preto, University of Sa˜o Paulo.
All experiments were carried out with 8-week-old male mice according to the
guidelines of the Animal Welfare Committee of the School of Medicine of Ribeira˜o
Preto, University of Sa˜o Paulo (protocol number: 120/2011).
Patients. Eleven adult patients admitted to the Emergency Department of the
School of Medicine of Ribeira˜o Preto with severe sepsis or septic shock between
October 2014 and November 2015, who met the inclusion/exclusion criteria and
survived after treatment of sepsis, were prospectively enroled into the study. In
addition, 14 healthy volunteers were also included in the study (Supplementary
Table 1). All patients enroled fulﬁlled the criteria deﬁned by the 2001 International
Sepsis Deﬁnitions Conference56. The exclusion criteria included active
haematological malignancy or cancer, chronic treatment with steroids,
transplantation, HIV infection or advanced cirrhosis. Peripheral blood samples
were collected from all patients 5–10 months after sepsis diagnosis. Informed
written consent from all participants was obtained. The study was approved by the
Human Subjects Institutional Committee of the Ribeira˜o Preto Medical School,
Brazil (Licence number: 30459114.6.0000.5440).
Caecal ligation and puncture model. Caecal ligation and puncture Model (CLP)
was performed as previously described12. Brieﬂy, mice were anaesthetized by
intraperitoneal (i.p.) administration of 200 ml ketamine and xylazine diluted in
phosphate-buffered saline (PBS) (100mg kg 1 ketamine, 10mg kg 1 xylazine).
A double puncture was made through the caecum with an 18-gauge needle to
induce a severe CLP sepsis. In experiments performed on BALB/c background,
mice received an i.p. injection of ertapenem sodium (30mg kg 1, Merck Research
Laboratory) beginning 6 h after CLP and then every 12 h up to day 4. In
experiments performed on the C57BL/6 J background mice, antibiotic were injected
i.p. up to day 3 after CLP.
Legionella pneumophila infection. Sepsis-surviving mice were infected with a
virulent clinical strain of L. pneumophila (serogroup 1, CR1326) as described
previously57. L. pneumophila were grown for 48 h on charcoal yeast extract agar
(1% yeast extract, 1% N-(2-acetamido)-2- aminoethanesulfonic acid, pH 6.9,
3.3mM L-cysteine, 0.33mM Fe(NO3), 1.5% bacto agar and 0.2% activated
charcoal). Mice were inoculation intranasally with 40 ml of a suspension containing
7 107 L. pneumophila.
Bacterial counts. Measurement of L. pneumophila in lung and spleen was
determined as previously described12. Brieﬂy, 24 h after infection, lungs and spleen
were explanted and placed in sterile tubes containing 10ml or 500 ml of distilled
H2O, respectively. Lungs and spleen were homogenized for 30 s with a PowerGen
125 homogenizer (Fisher Scientiﬁc). Dilutions of the lung lysate and spleen lysate
were plated on charcoal yeast extract agar for determination of colony-forming
units per organ.
Treatment of mice. In some experiments, mice were treated intranasally with 1 or
3 mg recombinant murine IL-33 (BioLegend) in a volume of 40 ml per mouse or PBS
for 4 consecutive days (once a day). On day 6 after ﬁrst IL-33 treatment, mice were
inoculation with a sub-lethal dose of L. pneumophila. Mice were killed on day
2-post infection, and bacterial loads analysed. FACS analysis was performed on day
7-post the ﬁrst inoculation of IL-33 to identify M2 macrophage populations.
Cytokine analysis was performed on day 8 after IL-33 administration17. In another
set of experiment, mice were treated with recombinant murine sST2, which was
produced at the VIB Protein Service Facility, VIB Inﬂammation Research Center
(Ghent, Belgium) and kindly provided by Dr Rudi Beyaert. Mice were injected
subcutaneously with 100mg of sST2 in a volume of 200 ml per mouse or PBS on
days 1.5, 3, 5, 7, 9, 11 and 13 after CLP (once a day). At ﬁfteenth day after CLP,
surviving mice were challenged intranasally with a sublethal dose of L.
pneumophila.
Macrophage differentiation and polarization. BMDM were differentiated as
described previously17. Bone marrow cells from WT mice were cultured in the
presence of M-CSF (20 ngml 1, R&D Systems) in a petri dish (BD OPTILUX).
After 7 days, the macrophages (1 107 per 10ml) were stimulated with IL-4
(30 ngml 1, R&D Systems), IL-13 (30 ngml 1, R&D Systems), IL-33
(30 ngml 1, BioLegend) (M2 differentiation); or LPS (1 mgml 1, E. coli 0111:B4,
Sigma-Aldrich), IFN-g (200 ngml 1, R&D Systems), M-CSF (5 ngml 1, R&D
Systems) (M1 differentiation); or M-CSF (5 ngml 1, R&D Systems) alone
(M0 macrophages) for 2 days. In some experiments, macrophages were cultured
with 10 ngml 1 IL-4 (R&D Systems) and/or 20 ngml 1 IL-33 (BioLegend) for 2
days. At the end of cultures, the cells were used for FACS and supernatants for
cytokine analysis by ELISA.
M2 macrophages adoptive transfer. M0 or M2-polarized macrophages derived
from bone marrow (BMDM) or vehicle (PBS) were injected i.v. to naive and sepsis-
surviving WT and Stat6 / mice (4 106 cells per mouse, on day 3 after CLP).
The recipient mice were then infected i.n. with L. pneumophila on day 15 after
CLP.
Coculture of macrophages with T cells. Subsets of macrophages (M0, M1 or M2,
5 105 per well) were co-cultured for 4 days with effector CD4þ T cells (CD4þ
CD25T cells, 5 105 per well) puriﬁed from the spleen of WT or Il10 / naive
mice, in the presence of IL-2 (10 ngml 1, R&D Systems), anti-IL-10 (50 mgml 1,
clone JES052A5, R&D Systems) and stimulated with polyclonal anti-CD3
(1 mgml 1, BD Biosciences) in U-bottom 96-well plates. Cells were then stained
for Foxp3 and CD4 and analysed by FACS.
Isolation of CD11bþ macrophage-enriched lung population. Lung tissue was
digested with DNAse I (Sigma) and Liberase TL (Roche) for 45min at 37 C under
rotation. Total lung cells were stained with speciﬁc antibody to anti-CD11b
(M1/70, BioLegend) for 15min. After that, cells were puriﬁed using anti-PE
magnetic beads in AutoMACS (Miltenyi Biotec) according to manufacturer’s
instructions.
ELISA. Cytokine concentrations in serum, lung and peritoneal lavages, and che-
mokine concentration in lung and culture supernatants were determined by ELISA
according to each manufacturer’s instructions. Antibody pairs or kits were
obtained for IL-4, IL-10, IL-13 (eBioscience), IL-6 (BD Biosciences) and IL-1b, IL-
33, IGF-1, TNF, CCL17, CCL22, Endocan-1 (R&D Systems). It was not speciﬁed in
the manufacturer’s datasheet if the IL-33 kit can distinguish between pro-IL-33 and
cleaved IL-33.
Western blotting. Arginase 1 expression in peritoneal cells was determined by
western blotting according to manufacturer’s directions. Brieﬂy, the nitrocellulose
membrane was incubated with polyclonal sheep anti-mouse Arginase 1 (#AF5868,
R&D Systems) at 4 C overnight, followed by incubation with anti-sheep IgG,
horseradish peroxidase-linked secondary antibody and developed using
enhanced chemiluminescence technique (ChemiDoc XRS System, Bio-Rad
Laboratories). The membrane was stripped and reprobed with Gapdh as a loading
control. Full scan of the original uncropped western blot is shown in
Supplementary Fig. 13.
Gene expression by qPCR. Total RNA from lung tissue was extracted using the
TRIZOL reagent (Invitrogen) according to manufacturer’s directions. For the
CD11bþ cells isolated from lung tissues, the total RNA was extracted using
RNeasy Mini Kit (Qiagen) according to manufacturer’s instructions. Total RNA
(2 mg for lung tissue and 400 ng for CD11bþ cells) was reverse-transcribed using
high capacity cDNA RT Kit (Thermo Fisher Scientiﬁc). Quantitative real-time PCR
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was performed using TaqMan Gene Expression Master Mix or Power Syber Green
PCR Master Mix TaqMan (Thermo Fisher Scientiﬁc) and the Viia7 Real-Time PCR
system. All data were normalized to Gapdh values; and results were analysed using
comparative Ct method (or DDCt method). The relative gene expression is pre-
sented as the fold-increase over that seen in naive WT controls. qPCR was per-
formed using Taqman primers (Thermo Fisher Scientiﬁc) for Cebpb
(Mm00843434_s1), Arg1 (Mm00475988_m1), Mrc1 (Mm00485148_m1), Igf1
(Mm00439560_m1) and Gapdh (Mm99999915_g1). For the CD11bþ cells isolated
from lung tissues, qPCR was performed using syber primers for Retnla (Foward:
CCT GAG ATT CTG CCC CAG GAT, reverse: TTC ACT GGG ACC ATC AGC
TGG), Mrc1 (Forward: CTC GTG GAT CTC CGT GAC AC, reverse: GCA AAT
GGA GCC GTC TGT GC) and Gapdh (forward: GGG TGT GAA CCA CGA GAA
AT, reverse: CCT TCC ACA ATG CCA AAG TT).
Flow cytometry. Aliquots of freshly harvested cells (1 106 cells per tube) were
suspended in buffer containing 2% FCS in PBS. To stain for surface antigens, cells
were incubated with speciﬁc antibodies to F4/80 (BM8, eBioscience), CD206
(mannose receptor C type 1, MR; MR5D3, AbD Serotec), CD4 (GK1.5, eBioscience;
H129.19, BD Biosciences), CD4 (RPA-T4, BD Biosciences, for human), CD45 (30-
F11, BD Biosciences), Ly-6A/E (Sca-1; E13-161.7, BioLegend), CD3e (145-2C11,
BD Biosciences), CD8a (53-6.7, eBioscience), CD19 (eBIO1D3, 1D3, eBioscience;
6D5, BioLegend), CD11b (M1/70, BioLegend), CD11c (N418, BioLegend; Hl3, BD
Biosciences), CD49b/Pan-NK (DX5, BD Biosciences), FceRI Alpha (MAR-1,
eBioscience), T1/St2 (IL-33R, DJ8, MD Biosciences) or the appropriate isotype
controls for 30min. To stain for intracellular murine antigens, cells were ﬁrst
stained for surface antigens, then ﬁxed and permeabilized with mouse Foxp3 Buffer
Set (BD Biosciences), according to the manufacturer’s recommendations. Cells
were then incubated with speciﬁc antibodies to FoxP3 (FJK-16 s, eBioscience),
FoxP3 (150D/E4, eBioscience, for human) or IL-13 (eBio13A, eBioscience) for
45min. For intracellular IL-13 staining, cells were incubated with phorbol-12-
myristate-13-acetate (Sigma-Aldrich), ionomycin (750 ngml 1, Sigma-Aldrich)
and GolgiStop (BD Biosciences) for 4 h. To stain pSTAT6, cells were incubated
with rmIL-4 (30 ngml 1, R&D Systems) or medium for 15min at 37 C. Cells
were then washed in PBS, ﬁxed immediately in formaldehyde (ﬁnal concentration
2%) for 10min at 37 C, washed and re-suspended in ice-cold methanol for 30min
at 4 C. Cells were washed twice in staining buffer and stained with an antibody
speciﬁc for pSTAT6 (pY641, BD Biosciences) and F4/80 (BM8, eBioscience) or the
appropriate isotype controls. Cells were analysed by FACSCanto using FCS Express
V3 (De Novo Software, Los Angeles, CA). Gating strategies for ﬂow cytometry
analysis are shown in Supplementary Fig. 14.
Intracellular growth of bacteria on macrophage. Macrophages from bone
marrow–derived macrophages (BMDM) or peritoneal cells were added to 24-well
plates at a density of 2.5 105 cells per well. L. pneumophila bacteria were added to
each well at an MOI of 0.1 in the presence of BEC (S)-(2-Boronoethyl)-L-cysteine)
or medium alone. On the third day, macrophages were lysed in sterile H2O, and the
cell lysates were plated for counted of bacteria colonies present after 4 days of
incubation at 37 C (ref. 57). The results are expressed as log of colony-forming
units (log CFU per ml).
Measurements of organ damage biomarkers. Liver injury was assessed by
measuring the increase in serum concentrations of alanine aminotransferase; renal
dysfunction was assessed by the increase in blood urea nitrogen, and creatine
kinase-MB was used as an index of cardiac lesions. The determinations were
performed using a commercial kit (Labtest).
Statistical analysis. Prism 5 software (GraphPad Software) was used to analyse
data by two-tailed unpaired Student’s t-tests. When CLP groups were compared
with a control group, one-way ANOVA result with Dunnett posthoc tests was
performed. Data are presented as means±s.e.m. Survival studies were analysed
with the Mantel–Cox log-rank test, and bacterial counts were analysed by the
Mann–Whitney U test and presented as median. Po0.05 was considered statisti-
cally signiﬁcant. No pre-speciﬁed effect size was assumed, and in general three mice
or replicates for each group were used in experiments; this sample size was sufﬁ-
cient to demonstrate statistically signiﬁcant differences in comparisons between
two unpaired experimental groups by an unpaired t-test, multiple comparations by
one-way ANOVA result with Bonferroni posthoc tests or comparison with a
control group, one-way ANOVA result with Dunnett posthoc tests. Since all mouse
strains were generated and maintained on the same original inbred background
(BALB/c or C57BL/6 J), the variation within each data set obtained by experiments
with primary cells or mice was assumed to be similar between genotypes. However,
experimental assessment of variance was not performed. Mice were to be excluded
from analysis only if they displayed obvious illness or death. No randomization was
used in these studies. Human experiments were blinded on samples group.
However, we were not blinded to genotypes or group allocations during animal
experiments.
Data availability. The data supporting the ﬁndings of this study are available
within the article and its supplementary information ﬁles or from the corre-
sponding authors on reasonable request.
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